Scaling continuous fermentation for lower-cost biomanufacturing.
Photo credit: Cauldron / cauldronferm.com
Cauldron is a biomanufacturing company developing continuous precision-fermentation processes for food, feed, fiber, nutrition, materials, and other biological products. Founded in 2022 and led by founder and CEO Michele Stansfield, it acquired technology and facilities from Agritechnology and operates a demonstration site in Orange, New South Wales.
Its “hyper-fermentation” platform keeps microorganisms producing over extended campaigns rather than emptying, cleaning, and restarting a vessel after each conventional batch. Cauldron works as a contract development and manufacturing organization, adapting customer organisms and products to its process while emphasizing contamination control, stable production strains, downstream recovery, and repeatable operating conditions.
The scale distinction is important. Public reporting described the Orange operation as a 25,000-liter-capacity demonstration facility, while Cauldron’s planned Mackay, Queensland Bio-fab is designed for 500,000 liters of total fermentation capacity. As of September 17, 2026, government backing, site plans, and financing had been announced, but public evidence did not establish that the 500,000-liter facility was commissioned or producing commercially. The company’s claim that a 100,000-liter continuous line could outproduce a 500,000-liter batch line is a projected productivity comparison, not proof that Cauldron already operates a 500,000-liter reactor.
Cauldron aims to make fermentation-derived ingredients economical at higher volumes by increasing productive uptime and output per unit of installed vessel capacity. If validated for a customer’s organism and product, continuous operation could require smaller facilities, less repeated cleaning and sterilization, and lower capital per kilogram than conventional fed-batch production. Those economics could help replace some resource-intensive animal, petrochemical, or agricultural inputs.
Environmental benefits cannot be assigned to the platform in the abstract. Fermentation impacts depend on feedstock, electricity, heating and cooling, oxygen transfer, purification, product yield, and the incumbent product displaced. Cauldron has not published a peer-reviewed facility life-cycle assessment or audited commercial campaign data. Continuous cultures also face contamination, genetic stability, and downstream-processing risks, and projected capital or energy savings should remain separate from operating achievements.
Cauldron’s established operating reference is its Orange demonstration facility, reported at 25,000 liters of fermentation capacity. Company and trade reporting describe continuous campaigns and customer proof cases at industrially relevant scale, but public materials do not disclose complete run lengths, yields, contamination rates, customer product volumes, or independently verified cost per kilogram.
The planned Mackay Bio-fab has been described as a 500,000-liter facility supported by the Queensland government. That figure represents planned total facility capacity, not an achieved single-vessel run or current output. Cauldron says a 100,000-liter hyper-fermentation line could produce more than a 500,000-liter batch line and use substantially less capital; these are company projections that depend on organism, titer, productivity, recovery, and uptime.
Cauldron reported A$20 million in cumulative funding after its 2024 Series A and announced a further A$13.25 million Series A2 in 2026. A separate A$4.3 million government grant announced in 2025 supports technical development. Financing and construction support are scale-up milestones, not evidence that the Mackay plant is operational.
Extended continuous production
The platform is designed to keep validated microbial cultures producing across longer campaigns instead of restarting after every batch.
Higher output per installed vessel
Greater productive uptime could let customers target a given annual volume with less fermentation capacity than a batch-only process.
Contract scale-up pathway
Cauldron adapts customer organisms and recovery processes from development through demonstration without requiring each company to build a plant.
Flexible biological manufacturing
The process is being developed for proteins, fats, oils, materials, and other products across food, feed, nutrition, and industrial markets.
Focus areas
Locations
